Correction:IGF-1R is a molecular determinant for response to p53 reactivation therapy in conjunctival melanoma (Oncogene, (2022), 41, 4, (600-611), 10.1038/s41388-021-02111-x)
Autor: | Song, Dawei, Cismas, Sonia, Crudden, Caitrin, Trocme, Eric, Worrall, Claire, Suleymanova, Naida, Lin, Tingting, Zheng, Huiyuan, Seregard, Stefan, Girnita, Ada, Girnita, Leonard |
---|---|
Přispěvatelé: | Pathology, CCA - Cancer biology and immunology |
Jazyk: | angličtina |
Rok vydání: | 2023 |
Zdroj: | Song, D, Cismas, S, Crudden, C, Trocme, E, Worrall, C, Suleymanova, N, Lin, T, Zheng, H, Seregard, S, Girnita, A & Girnita, L 2023, ' Correction : IGF-1R is a molecular determinant for response to p53 reactivation therapy in conjunctival melanoma (Oncogene, (2022), 41, 4, (600-611), 10.1038/s41388-021-02111-x) ', Oncogene, vol. 42, no. 11, pp. 858 . https://doi.org/10.1038/s41388-023-02607-8 Oncogene, 42(11). Nature Publishing Group |
ISSN: | 0950-9232 |
DOI: | 10.1038/s41388-021-02111-x) |
Popis: | Following the publication of this article, the authors noted errors in the assembly of Fig. 2b. A corrected version is provided in which the western blot panel for the cell line CM2 has been replaced with images from an alternative repeat for the pIGF1R/IGF1R and pAkt/Akt. In addition, the CM1 panel is updated with longer exposure images for pIGF1R/IGF1R and pAkt to better demonstrate the absence of IGF1R and IGF1-induced signaling activation in this cell line. The description of the results and the figure legend remain unchanged, and the authors confirm that conclusions of this article are not affected by this correction. The authors apologize for any inconvenience this may have caused for readers. |
Databáze: | OpenAIRE |
Externí odkaz: |